NEW YORK– Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Matt Wiley as its Chief Commercial Officer (CCO). In his new role, Mr. Wiley will serve as a member of the executive team, overseeing the Company’s commercial vision and strategy as it prepares for the potential launch of its first product, MM120 orally disintegrating tablet (ODT) for generalized anxiety disorder (GAD) and major depressive disorder (MDD).
“Matt’s deep experience in launching multiple neuroscience and psychiatric therapeutics will be invaluable as we prepare for our first potential FDA approval of MM120 ODT,” said Rob Barrow, Chief Executive Officer of MindMed. “His proven track record in driving commercial success for novel, first-in-class products like XYREM® will be an asset in realizing the significant commercial potential of MM120. As we approach multiple key clinical readouts from our Phase 3 development program in 2026, I look forward to partnering with Matt during our next phase of growth, bringing transformational innovation to the more than 50 million people suffering from anxiety and depression.”
“Joining MindMed at this pivotal moment is an exciting and deeply inspiring opportunity to help redefine psychiatric care,” said Mr. Wiley. “With MM120 ODT supported by a strong and thorough clinical development program, I firmly believe it has the potential to be a game-changing therapy. I’m eager to work alongside a team that shares my dedication to improving patients’ lives by addressing anxiety and depression—two of the most widespread and critical challenges in today’s mental health crisis.”
Mr. Wiley has more than 25 years of sales, marketing, and strategic leadership experience across multiple specialty product launches. He joins MindMed from BioXcel Therapeutics, where he served as CCO overseeing the launch of the company’s first acute treatment of agitation associated with schizophrenia and bipolar disorder. Prior to BioXcel, Mr. Wiley served as CCO at VYNE Therapeutics, overseeing all commercial objectives related to the launch of the company’s first two dermatology products. Before this, he served as Vice President of Marketing and Business Unit Lead for Jazz Pharmaceuticals’ sleep medicine unit, where he led commercial strategies for the company’s treatments for narcolepsy and sleep apnea and developed the successful growth strategy for XYREM® for narcolepsy, which achieved blockbuster status over his tenure. He also served as Vice President of Marketing at Azur Pharma, supporting the startup of U.S. operations and the company’s acquisition by Jazz Pharmaceuticals. In addition, Mr. Wiley held roles of increasing responsibility at Cephalon, Salix Pharmaceuticals, and MGI Pharma. He holds a Bachelor of Arts in English from Syracuse University.
In connection with his appointment as Chief Commercial Officer, MindMed granted Mr. Wiley inducement awards consisting of (i) an option to purchase an aggregate of 350,000 common shares of the Company (the “Option”) and (ii) 125,000 performance stock units (the “PSUs”) (assuming achievement at target levels of performance) that, if earned, will be settled in MindMed common shares upon vesting, each with an effective grant date of March 17, 2025. The Option has an exercise price equal to the closing price of MindMed’s common shares on March 14, 2025, the last trading day on which MindMed’s common shares traded prior to the date of the grant and will vest over a four-year period with 25% vesting on the first anniversary and the remaining 75% vesting in 36 equal monthly installments over the three-year period thereafter, subject to his continued employment. The PSUs will vest on the third anniversary of the grant date, subject to continued service through the vesting date. Actual earned PSUs can range from 0%-200% of the target number of PSUs and will be based on the achievement of certain performance metrics as measured at the end of the three-year performance period.
The inducement awards to Mr. Wiley were granted as a material inducement to his employment and were approved by MindMed’s Compensation Committee on March 11, 2025, in accordance with Rule 5635(c)(4) of The NASDAQ Stock Market LLC. The awards were granted outside MindMed’s equity incentive plans.
